Statistical properties of Continuous Composite Outcomes: Implications for clinical trial design

被引:2
|
作者
Troy, Jesse D. [1 ,2 ]
Simmons, Ryan A. [2 ]
机构
[1] Duke Univ, Marcus Ctr Cellular Cures, Sch Med, Durham, NC 27706 USA
[2] Duke Univ, Dept Biostat & Bioinformat, Sch Med, 424 Erwin Rd Suite,1102 Hock Plaza Box 2721, Durham, NC 27710 USA
关键词
Clinical trials; Treatment outcome; Statistics;
D O I
10.1016/j.conctc.2020.100655
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Statistical efficiency can be gained in clinical trials by using composites of time-to-event outcomes when the individual component outcomes have low event rates. However, the utility of continuous composite outcome measures is not as clear. Efficiency can be either gained or lost by using a continuous composite outcome measure depending on several factors, including the strength of correlation between the component outcomes and the size of the treatment effect on each component. In this article we review these concepts from the standpoint of planning a new trial. Statistical properties of composites formed from normally distributed continuous outcomes are discussed. An example dataset is used to demonstrate concepts and complete mathematical details are provided. Finally, a conceptual model for clinical trial design with continuous composites is proposed that could be used as a guide to evaluate the utility of a continuous composite outcome in a future trial based on existing knowledge in the therapeutic area.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Clinical trial design in the era of precision medicine
    Elena Fountzilas
    Apostolia M. Tsimberidou
    Henry Hiep Vo
    Razelle Kurzrock
    Genome Medicine, 14
  • [42] Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: Implications for clinical trial design
    Tjandra, T
    Brooks, JCW
    Figueiredo, P
    Wise, R
    Matthews, PM
    Tracey, I
    NEUROIMAGE, 2005, 27 (02) : 393 - 401
  • [43] Will genetic profiling make a difference in clinical trial outcomes?
    Conti, C. Richard
    CLINICAL CARDIOLOGY, 2008, 31 (03) : A6 - 99
  • [44] Clinical trial design in the era of precision medicine
    Fountzilas, Elena
    Tsimberidou, Apostolia M.
    Vo, Henry Hiep
    Kurzrock, Razelle
    GENOME MEDICINE, 2022, 14 (01)
  • [45] The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial
    Abdalla, Safa
    Montez-Rath, Maria E.
    Parfrey, Patrick S.
    Chertow, Glenn M.
    CONTEMPORARY CLINICAL TRIALS, 2016, 48 : 119 - 124
  • [46] The Impact of Independent Statistical Analysis on Reported Outcomes in Cardiovascular Clinical Trials
    Esquitin, Ricardo
    Iyengar, Rupa L.
    Shah, Kshitij A.
    Razzouk, Louai
    Bashee, Sameer
    Aneja, Ashish
    Mathew, Verghese
    Farkouh, Michael E.
    CIRCULATION, 2010, 122 (21)
  • [47] Composite Outcomes for Clinical Trials in Critical Care: The Devil is in the Detail
    Ganesan, Saptharishi Lalgudi
    Parameswaran, Narayanan
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2020, 24 (10) : 903 - 904
  • [48] Statistical properties of the combined emission of a discrete source population: Astrophysical implications
    Grimm, Hans-Jakob
    Gilfanov, Marat
    Sunyaev, Rashid
    CHINESE JOURNAL OF ASTRONOMY AND ASTROPHYSICS, 2006, 6 : 197 - 204
  • [49] Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review
    Ensor, Hannah
    Lee, Robert J.
    Sudlow, Cathie
    Weir, Christopher J.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (05) : 859 - 879
  • [50] Trends in clinical trials in surgical oncology: Implications for outcomes research
    Guller, U
    Blumenstein, BA
    CLINICAL THERAPEUTICS, 2003, 25 (02) : 684 - 698